Page 169 - 2021_05-Haematologica-web

Mantle cell lymphoma with MYC-R
References
1.Jares P, Colomer D, Campo E. Molecular pathogenesis of mantle cell lymphoma. J Clin Invest. 2012;122(10):3416-3423.
2.Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017; 92(8):806-813.
3. AMaddocks K. Update on mantle cell lym- phoma. Blood. 2018;132(16):1647-1656. 4.Sander B, Quintanilla-Martinez L, Ott G,
Xerri L, Kuzu I, Chan JK, et al. Mantle cell lymphoma--a spectrum from indolent to aggressive disease. Virchows Arch. 2016;468(3):245-257.
5.Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lym- phoma in transgenic mice. EMBO J. 1994;13(15):3487-3495.
6. Hao S, Sanger W, Onciu M, Lai R, Schlette EJ, Medeiros LJ. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002;15(12):1266-1272.
7. Onciu M, Schlette E, Medeiros LJ, Abruzzo LV, Keating M, Lai R. Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol. 2001;116(6):886-892.
8.Klapproth K, Wirth T. Advances in the understanding of MYC-induced lym- phomagenesis. Br J Haematol. 2010; 149(4):484-497.
9. Sewastianik T, Prochorec-Sobieszek M, Chapuy B, Juszczynski P. MYC deregula- tion in lymphoid tumors: molecular mech- anisms, clinical consequences and thera- peutic implications. Biochim Biophys Acta. 2014;1846(2):457-467.
10. Kluin PM, Harris NL, Stein H, et al. High- grade B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC. 2017:335-341.
11.Swerdlow SH, Campo E, Seto M, and Muller-Hermelink H.K. Mantle cell lym- phoma. In: Swerdlow SH, Campo E, Harris NL, et al, ed. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon, France: IARC. 2017.
12.Lin P, Dickason TJ, Fayad LE, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lym- phoma. Cancer. 2012;118(6):1566-1573.
13. Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double-hit lym- phoma who achieve first complete remis- sion. J Clin Oncol. 2017;35(20):2260-2267.
14.Li S, Lin P, Fayad LE, et al. B-cell lym- phomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous his- tology, germinal center B-cell immunophe- notype and poor outcome. Mod Pathol. 2012;25(1):145-156.
15. Li S, Saksena A, Desai P, et al. Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma. Oncotarget. 2016;7(25):38122- 38132.
16. Li S, Seegmiller AC, Lin P, et al. B-cell lym- phomas with concurrent MYC and BCL2 abnormalities other than translocations
behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol. 2015;28(2):208- 217.
17. Li S, Huang W, Oki Y, Medeiros JL. MYC/BCL2/BCL6 triple hit lymphoma: A study of 33 patients who had an aggressive clinical course similar to patients with dou- ble hit lymphomas. J Clin Oncol. 2017; (35):7559.
18. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354-2361.
19.Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classi- fication. Blood. 2013;122(24):3884-3891.
20. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011; 117(8):2319-2331.
21. Li S, Desai P, Lin P, et al. MYC/BCL6 dou- ble-hit lymphoma (DHL): a tumour associ- ated with an aggressive clinical course and poor prognosis. Histopathology. 2016;68(7):1090-1098.
22. Landsburg DJ, Petrich AM, Abramson JS, et al. Impact of oncogene rearrangement pat- terns on outcomes in patients with double- hit non-Hodgkin lymphoma. Cancer. 2016; 122(4):559-564.
23. Kluin PM., Campo E, Harris NL, Jaffe ES, et al. High Grade B-Cell Lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, et al., ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition ed. Lyon, France: IARC. 2017.
24. Au WY, Horsman DE, Viswanatha DS, Connors JM, Klasa RJ, Gascoyne RD. 8q24 translocations in blastic transformation of mantle cell lymphoma. Haematologica. 2000;85(11):1225-1227.
25. Delas A, Sophie D, Brousset P, Laurent C. Unusual concomitant rearrangements of Cyclin D1 and MYC genes in blastoid vari- ant of mantle cell lymphoma: case report and review of literature. Pathol Res Pract. 2013;209(2):115-119.
26. Hu Z, Medeiros LJ, Chen Z, et al. Mantle cell Lymphoma with MYC rearrangement: a report of 17 patients. Am J Surg Pathol. 2017;41(2):216-224.
27. Reddy K, Ansari-Lari M, Dipasquale B. Blastic mantle cell lymphoma with a Burkitt translocation. Leuk Lymphoma. 2008;49(4):740-750.
28. Setoodeh R, Schwartz S, Papenhausen P, et al. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the lit- erature. Int J Clin Exp Pathol. 2013; 6(2):155-167.
29. Xu J, Li S. Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia. Blood. 2017;129(18):2593.
30. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classifica- tion of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275-282.
31. Slotta-Huspenina J, Koch I, de Leval L, et al. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lym- phoma: p53 alterations and blastoid mor- phology are strong predictors of a high pro- liferation index. Haematologica. 2012; 97(9):1422-1430.
32. Visco C, Tzankov A, Xu-Monette ZY, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irre-
spective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013;98(2):255-263.
33. Ribera-Cortada I, Martinez D, Amador V, et al. Plasma cell and terminal B-cell differ- entiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. Mod Pathol. 2015;28(11):1435-1447.
34. Saksena A, Yin CC, Xu J, et al. CD23 expression in mantle cell lymphoma is associated with CD200 expression, leukemic non-nodal form, and a better prognosis. Hum Pathol. 2019;89:71-80.
35. Huang W, Medeiros LJ, Lin P, et al. MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. Mod Pathol. 2018;31(9):1470- 1478.
36. McGowan-Jordan J, Simons A, Schmid M. An International System for Human Cytogenetic Nomenclature (ISCN 2016), Recommendations of the International Standing Commitee on Human Cytogenetic Nomenclature. Unionville, USA: Karger. 2016.
37. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lym- phoma. Blood. 2008;111(12):558-565.
38. ZhouJ,HuL,ZuoM,ZhouY,LiG,Zhang X. An uncommon case of double-hit man- tle cell lymphoma that demonstrates a transformation process. Am J Clin Pathol. 2019;153(1):49-57.
39. Vincent-Fabert C, Fiancette R, Rouaud P, et al. A defect of the INK4-Cdk4 checkpoint and Myc collaborate in blastoid mantle cell lymphoma-like lymphoma formation in mice. Am J Pathol. 2012;180(4):1688-1701.
40. Lee J, Zhang LL, Wu W, et al. Activation of MYC, a bona fide client of HSP90, con- tributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018; 2(16):2039-2051.
41. Zhang X, Chen X, Lin J, et al. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene. 2012;31(24):3002-3008.
42. Chisholm KM, Bangs CD, Bacchi CE, Molina-Kirsch H, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39(3):294-303.
43. Oberley MJ, Rajguru SA, Zhang C, et al. Immunohistochemical evaluation of MYC expression in mantle cell lymphoma. Histopathology. 2013;63(4):499-508.
44. Wang XJ, Medeiros LJ, Lin P, et al. MYC cytogenetic status correlates with expres- sion and has prognostic significance in patients with MYC/BCL2 protein double- positive diffuse large B-cell lymphoma. Am J Surg Pathol. 2015;39(9):1250-1258.
45. Miao Y, Lin P, Wang W, Jeffrey Medeiros L, Lu X. CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma. Am J Clin Pathol. 2016; 146(6):747-752.
46. Yi S, Zou D, Li C, et al. High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnor- mality predicts poor survival. Oncotarget. 2015;6(39):42362-42371.
47. Quesada AE, Medeiros LJ, Desai PA, et al. Increased MYC copy number is an inde- pendent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017;30(12):1688-1697.
haematologica | 2021; 106(5)
1389